Aisling Capital’s Intersect ENT, Inc XENT Stock Holding History

Aisling Capital’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-225,000	Closed	-$3.86M	–	16
2017 Q1	$3.86M	Hold	225,000	–	–	0.7%	14
2016 Q4	$2.72M	Sell	225,000 -23,498	-9%	-$304K	0.63%	15
2016 Q3	$3.94M	Sell	248,498 -201,502	-45%	-$3.03M	0.81%	16
2016 Q2	$5.82M	Buy	450,000 +100,000	+29%	+$1.57M	1.37%	17
2016 Q1	$6.65M	Hold	350,000	–	–	1.33%	17
2015 Q4	$7.88M	Hold	350,000	–	–	1.36%	16
2015 Q3	$8.19M	Hold	350,000	–	–	1.44%	17
2015 Q2	$10M	Hold	350,000	–	–	1.49%	16
2015 Q1	$9.04M	Hold	350,000	–	–	1.18%	16
2014 Q4	$6.49M	Hold	350,000	–	–	0.98%	16
2014 Q3	$5.43M	Buy	+350,000	New	+$5.27M	1.05%	17

Other funds holding XENT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Aisling Capital's XENT Position: Q2 2017 in Review

Aisling Capital sold out of Intersect ENT, Inc (XENT) in Q2 2017, closing a stake of 225,000 shares — an estimated $3.86M sold.

Aisling Capital first reported a position in XENT in Q3 2014 and held it in 11 quarters. The position peaked at $10M in Q2 2015. 128 funds tracked by Wall St. Rank hold XENT as of Q2 2017.

Aisling Capital reported no remaining Intersect ENT, Inc position as of Q2 2017 after selling out during the quarter.
Aisling Capital sold 225,000 Intersect ENT, Inc shares in Q2 2017, an estimated $3.86M.
Aisling Capital first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 11 quarters.
Aisling Capital's Intersect ENT, Inc position peaked at $10M in Q2 2015.
128 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2017.

Based on Aisling Capital's 13F filing for Q2 2017, filed 14 Aug 2017.